Laura F Newell MD
Instructor, Medicine, Oregon Health and Science University School of Medicine
Join to View Full Profile
3181 SW Sam Jackson Park Rd# L586Portland, OR 97239
Phone+1 503-494-6346
Fax+1 503-346-8015
Dr. Newell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2007 - 2010
University of California Davis HealthResidency, Internal Medicine, 2004 - 2007
University of California, Davis, School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2005 - Present
OR State Medical License 2011 - 2025
WA State Medical License 2007 - 2012
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Publications & Presentations
PubMed
- Placental growth factor enhances inflammatory toll-like receptor responses in syncytiotrophoblasts.Laura F Newell, Shernan G Holtan, Leena Kadam, Grover C Bagby, Leslie Myatt
Placenta. 2025-08-01 - 1 citationsVascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202.Laura F Newell, Najla El Jurdi, Brian C Betts, Corey Cutler, Joseph H Antin
Blood Vessels, Thrombosis & Hemostasis. 2024-09-01 - 1 citationsCPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.Scott R Solomon, Bayard L Powell, Jamie Koprivnikar, Catherine Lai, Heather Male
Cancers. 2024-02-24
Abstracts/Posters
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...Laura F. Newell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
OHSU Second in Country to Perform Regenerative Brain Cell Therapy ProcedureNovember 3rd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
